Biogen & Eli Lilly and Company
6 shared events · Importance 3 · Last updated Aug 18, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Tech
Biogen: Biogen produces lecanemab (Leqembi), an anti-amyloid drug whose efficacy was challenged by the Cochrane review, which could negatively affect its market performance.
Eli Lilly and Company: Eli Lilly and Company produces donanemab (Kisunla), one of the anti-amyloid drugs whose effectiveness was questioned by the Cochrane review, potentially impacting its sales and stock price.
Apr 16, 2026 · 6 articles
Tech
Biogen: Biogen is a member of the pre-competitive consortium that collaborated on the CNS-102 study. The results may inform its ALS and FTD clinical trial designs.
Eli Lilly and Company: Eli Lilly is a consortium member. The study's results could support its use of multimodal home-based assessments in CNS trials.
Aug 18, 2026 · 6 articles
Business
Biogen: Biogen collaborates with Eisai on Leqembi development and commercialization, benefiting from the India launch through co-commercialization.
Eli Lilly and Company: Eli Lilly faces increased competition in India's Alzheimer's market as Eisai launches Leqembi, potentially impacting its Lormalzi uptake.
Aug 03, 2026 · 6 articles
Business
Biogen: Biogen was an early partner of Scribe, providing initial backing. While not directly involved in the IPO, the partnership highlights Scribe's early validation.
Eli Lilly and Company: Eli Lilly has a strategic collaboration with Scribe, which may benefit from Scribe's successful IPO and pipeline progress.
Jul 06, 2026 · 25 articles
Tech
Biogen: Greta Duréel has consulted for Biogen, but no direct impact from this study.
Eli Lilly and Company: Greta Duréel has consulted for Eli Lilly, but no direct impact from this study.
Aug 12, 2026 · 6 articles
Business
Biogen: Biogen, in collaboration with Eisai, developed Leqembi, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Eli Lilly and Company: Eli Lilly and Company developed Kisunla, one of the FDA-approved monoclonal antibody treatments for Alzheimer's Disease, which requires a positive beta-amyloid brain scan.
Jul 06, 2026 · 6 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how Biogen and Eli Lilly and Company interact across events, view sentiment trends, and discover connected entities.
Open Dashboard